1. Home
  2. TPCS vs CALC Comparison

TPCS vs CALC Comparison

Compare TPCS & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TechPrecision Corporation

TPCS

TechPrecision Corporation

HOLD

Current Price

$4.45

Market Cap

40.9M

Sector

Industrials

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$4.40

Market Cap

63.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPCS
CALC
Founded
1956
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
40.9M
63.0M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TPCS
CALC
Price
$4.45
$4.40
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
49.1K
120.5K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$33,564,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.15
N/A
52 Week Low
$2.05
$1.42
52 Week High
$6.25
$4.82

Technical Indicators

Market Signals
Indicator
TPCS
CALC
Relative Strength Index (RSI) 47.67 59.59
Support Level $4.05 $4.09
Resistance Level $4.68 $4.75
Average True Range (ATR) 0.22 0.45
MACD -0.00 0.01
Stochastic Oscillator 55.88 69.97

Price Performance

Historical Comparison
TPCS
CALC

About TPCS TechPrecision Corporation

Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: